Kristen K Buck Caladrius Biosciences, Inc. (CLBS) insider trading activity

Kristen K Buck is EVP, R&D and CMO of CALADRIUS BIOSCIENCES, INC.. Currently has a direct ownership of 93,462 shares of CLBS, which is worth approximately $328,986. The most recent transaction as insider was on Jan 09, 2026, when has been sold 11,332 shares (Common Stock) at a price of $1.97 per share, resulting in proceeds of $22,324. This information was disclosed in a Form 4 filing with the Securities and Exchange Commission (SEC).

Shares Held (Direct Ownership) 93.5K

17.13% 3M change

17.13% 12M change

Total Value Held $328,986

Kristen K Buck Transaction History

Date	Transaction	Value	Shares Traded	Shares Held
Jan 09 2026	SELL Payment of exercise price or tax liability	$22,324 $1.97 p/Share	11,332 Reduced 10.81%	93,462 Common Stock
Jan 09 2026	BUY Grant, award, or other acquisition	-	25,000 Added 19.26%	104,794 Common Stock
Jan 10 2025	SELL Payment of exercise price or tax liability	$1,700 $3.73 p/Share	456 Reduced 0.57%	79,794 Common Stock
Jan 09 2025	SELL Payment of exercise price or tax liability	$28,203 $3.8 p/Share	7,422 Reduced 8.47%	80,250 Common Stock
Jan 09 2025	BUY Grant, award, or other acquisition	-	25,000 Added 22.19%	87,672 Common Stock
Oct 01 2024	SELL Payment of exercise price or tax liability	$18,643 $2.93 p/Share	6,363 Reduced 9.22%	62,672 Common Stock
Oct 01 2024	BUY Grant, award, or other acquisition	$43,950 $2.93 p/Share	15,000 Added 17.85%	69,035 Common Stock

Jan 10 2024	SELL Payment of exercise price or tax liability	$1,536 $3.0 p/Share	512 Reduced 0.94%	54,035 Common Stock
Jan 09 2024	SELL Payment of exercise price or tax liability	$16,533 $3.08 p/Share	5,368 Reduced 8.96%	54,547 Common Stock
Jan 09 2024	BUY Grant, award, or other acquisition	-	27,000 Added 31.06%	59,915 Common Stock
Sep 01 2023	SELL Payment of exercise price or tax liability	$6,339 $2.18 p/Share	2,908 Reduced 8.12%	32,915 Common Stock
Jan 10 2023	SELL Payment of exercise price or tax liability	$1,633 $3.19 p/Share	512 Reduced 1.41%	35,823 Common Stock
Jan 09 2023	SELL Payment of exercise price or tax liability	$6,441 $3.0 p/Share	2,147 Reduced 5.58%	36,335 Common Stock
Jan 09 2023	BUY Grant, award, or other acquisition	-	18,000 Added 31.87%	38,482 Common Stock
Sep 01 2022	SELL Payment of exercise price or tax liability	$34,980 $0.5 p/Share	69,959 Reduced 18.55%	307,244 Common Stock
Sep 01 2022	BUY Grant, award, or other acquisition	$29,000 $0.5 p/Share	58,000 Added 13.33%	377,203 Common Stock
Jan 10 2022	SELL Payment of exercise price or tax liability	$7,078 $0.92 p/Share	7,694 Reduced 2.35%	319,203 Common Stock
Jan 10 2022	BUY Grant, award, or other acquisition	-	64,500 Added 16.48%	326,897 Common Stock
Sep 01 2021	SELL Payment of exercise price or tax liability	$64,132 $1.28 p/Share	50,103 Reduced 16.03%	262,397 Common Stock
Sep 01 2021	BUY Grant, award, or other acquisition	-	312,500 Added 50.0%	312,500 Common Stock

KKB

Kristen K Buck

EVP, R&D and CMO

Basking Ridge, NJ

Institutional Portfolio Updates

Receive a notification when an Institution or Guru buys or sells CLBS shares.

Notify only if

Value

Insider Trading

Get notified when an Caladrius Biosciences, Inc. insider buys or sells CLBS shares.

Notify only if

Operation

Value

Type

News

Receive news related to CALADRIUS BIOSCIENCES, INC.

Track Activities on CLBS

Account